Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: temsirolimus, bevacizumab, sunitinib, interferon-alpha, advanced renal cell carcinoma, metastatic renal cell carcinoma, mTOR inhibitors, VEGF receptor inhibition, combination therapy, progression-free survival, targeted therapy, overall survival, quality of life, adverse events, proteinuria, thrombocytopenia
Open Access status: closed
OpenAlex ID: W2024586523
